IL10 and myeloid sarcoma: Studies in patients with MS receiving GA treatment confirmed a direct impact of GA on B cells, with reduced levels of activation markers and proinflammatory cytokines and increased IL-10 secretion and MHC-II expression (Hausler et al., 2020).